Current Status of Neuroendocrine Tumors with a Special Focus on Diagnosis and Novel Treatments—3rd Edition
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 30 September 2026 | Viewed by 37
Special Issue Editor
2. Department of Endocrine Tumors and Sarcomas, Karolinska University Hospital, Solna, Stockholm, Sweden
Interests: neuroendocrine tumors; bronchial carcinoids; peptide receptor radionuclide therapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue is the third edition of a previous issue on the topic of “Current Status of Neuroendocrine Tumors with a Special Focus on Diagnosis and Novel Treatments” (https://www.mdpi.com/journal/cancers/special_issues/neuroendocrine_tumors_diagnosis_novel_treatments) and “Current Status of Neuroendocrine Tumors with a Special Focus on Diagnosis and Novel Treatments—2nd Edition” (https://www.mdpi.com/journal/cancers/special_issues/6FY084HIJ5).
Neuroendocrine tumors are a growing group of tumors, the majority of which are malignant, with local or distant metastases at diagnosis. Tumors are divided according to their proliferative rate into neuroendocrine tumor grade 1, grade 2, and grade 3 (NET G1, G2, and G3, respectively) and neuroendocrine carcinoma (NEC). Most tumors are G1 and G2 and hence slow-growing, and patients suffering from such tumors may live for several years. Some tumors, especially neuroendocrine carcinomas, however, are highly proliferative, and patients affected by them have a short survival and poor prognosis. Most G1 and G2 tumors, and some G3 and NEC tumors, express somatostatin receptors and may be detected by somatostatin receptor imaging. Diagnostic sensitivity has improved with the introduction of 68Gallium-DOTATOC PET CT. Somatostatin analogs are the main treatment for patients with low proliferative tumors. Other treatments include chemotherapy, PRRT with 177Lutetium-DOTATATE, and targeted therapies, such as Everolimus, Sunitinib, and Cabozontinib, which have led to an improvement in prognosis. The need for newer therapeutic agents is, however, urgent.
This Special Issue will address current knowledge at the epidemiologic, diagnostic, molecular, and therapeutic levels, focusing on new diagnostic and therapeutic measures.
Dr. Dan Granberg
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- neuroendocrine tumors
- somatostatin analogues
- PRRT
- chemotherapy
- 68Gallium-DOTATOC
- PET
- CT
- targeted therapies
- mTOR
- inhibitors
- angiogenesis
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
